JP2021530971A5 - - Google Patents

Info

Publication number
JP2021530971A5
JP2021530971A5 JP2020571816A JP2020571816A JP2021530971A5 JP 2021530971 A5 JP2021530971 A5 JP 2021530971A5 JP 2020571816 A JP2020571816 A JP 2020571816A JP 2020571816 A JP2020571816 A JP 2020571816A JP 2021530971 A5 JP2021530971 A5 JP 2021530971A5
Authority
JP
Japan
Prior art keywords
seq
acid sequence
her2
tac
nucleic acid
Prior art date
Application number
JP2020571816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530971A (ja
JPWO2020018727A5 (https=
JP7404279B2 (ja
Filing date
Publication date
Priority claimed from US16/442,274 external-priority patent/US10640562B2/en
Application filed filed Critical
Priority claimed from PCT/US2019/042297 external-priority patent/WO2020018727A1/en
Publication of JP2021530971A publication Critical patent/JP2021530971A/ja
Publication of JP2021530971A5 publication Critical patent/JP2021530971A5/ja
Publication of JPWO2020018727A5 publication Critical patent/JPWO2020018727A5/ja
Application granted granted Critical
Publication of JP7404279B2 publication Critical patent/JP7404279B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020571816A 2018-07-17 2019-07-17 様々な構築物最適化を備えたt細胞抗原カプラ Active JP7404279B2 (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201862699173P 2018-07-17 2018-07-17
US62/699,173 2018-07-17
US201862703037P 2018-07-25 2018-07-25
US62/703,037 2018-07-25
US201862773120P 2018-11-29 2018-11-29
US62/773,120 2018-11-29
US201962826853P 2019-03-29 2019-03-29
US62/826,853 2019-03-29
US201962828879P 2019-04-03 2019-04-03
US62/828,879 2019-04-03
US201962839235P 2019-04-26 2019-04-26
US62/839,235 2019-04-26
US16/442,274 2019-06-14
US16/442,274 US10640562B2 (en) 2018-07-17 2019-06-14 T cell-antigen coupler with various construct optimizations
US201962874426P 2019-07-15 2019-07-15
US62/874,426 2019-07-15
PCT/US2019/042297 WO2020018727A1 (en) 2018-07-17 2019-07-17 T cell-antigen coupler with various construct optimizations

Publications (4)

Publication Number Publication Date
JP2021530971A JP2021530971A (ja) 2021-11-18
JP2021530971A5 true JP2021530971A5 (https=) 2022-07-14
JPWO2020018727A5 JPWO2020018727A5 (https=) 2022-07-14
JP7404279B2 JP7404279B2 (ja) 2023-12-25

Family

ID=69163917

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020571816A Active JP7404279B2 (ja) 2018-07-17 2019-07-17 様々な構築物最適化を備えたt細胞抗原カプラ

Country Status (12)

Country Link
EP (1) EP3823984A4 (https=)
JP (1) JP7404279B2 (https=)
KR (1) KR102834084B1 (https=)
CN (1) CN112689642B (https=)
AU (1) AU2019307905B2 (https=)
BR (1) BR112021000735A2 (https=)
CA (1) CA3104887A1 (https=)
IL (1) IL280049A (https=)
MX (1) MX2021000541A (https=)
PH (1) PH12021550114A1 (https=)
SG (1) SG11202100307WA (https=)
WO (1) WO2020018727A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459990B (zh) 2014-02-07 2021-06-01 麦克马斯特大学 三功能t细胞抗原偶联物及其制备方法和用途
WO2019071358A1 (en) 2017-10-12 2019-04-18 Mcmaster University Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
US10640562B2 (en) 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
WO2022226065A2 (en) 2021-04-21 2022-10-27 Conagen Inc. Biosynthetic production of delta-lactones using cytochrome p450 hydroxylase enzymes or mutants thereof
CA3173810A1 (en) 2021-06-01 2022-12-01 Andreas Bader Claudin 18.2 t cell-antigen couplers and uses thereof
US11453723B1 (en) * 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2794658T (lt) * 2011-12-19 2017-05-10 Synimmune Gmbh Bispecifinė antikūno molekulė
KR20150029714A (ko) * 2012-07-13 2015-03-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 이중특이적 항체의 공-도입에 의한 car 세포의 활성 증강
CN106459990B (zh) * 2014-02-07 2021-06-01 麦克马斯特大学 三功能t细胞抗原偶联物及其制备方法和用途
MX2017012939A (es) * 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
WO2016166139A1 (en) * 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
EP3472318B1 (en) * 2016-07-08 2023-09-06 Exuma Biotech Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
AU2017305524B2 (en) * 2016-08-04 2024-09-26 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
CN108250302A (zh) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多功能蛋白质

Similar Documents

Publication Publication Date Title
JP2021530971A5 (https=)
JP2022017333A5 (https=)
FI3599251T3 (fi) Cd20-antigeeniin kohdentuvan kimeerisen antigeenireseptorin rakentaminen ja sillä muunnettujen t-solujen aktiivisuuden tunnistaminen
IL259120A (en) Her2-targeted antigen chimeric receptors2
JP2008056679A5 (https=)
ES2676630T3 (es) Control inmunogénico de tumores y células tumorales
RU2020127887A (ru) Полипептиды транспозазы и их применение
JP2017160222A5 (https=)
JP2020517635A5 (https=)
JP2014088414A5 (https=)
JP2020500523A5 (https=)
WO2021147121A1 (zh) 修饰的免疫细胞及其应用
JP2017523184A5 (https=)
JP2013513377A5 (https=)
RU2021130306A (ru) Композиции il-12, нацеленные на edb
RU2016146389A (ru) Улучшенные полиэтилениминовые полиэтиленгликолевые векторы
JP2021501567A5 (https=)
JP2021527425A5 (https=)
CN115232217B (zh) 一种SynNotch结构及其应用
WO2015172563A1 (zh) 一种靶向eps8与egfr结合的短肽及其应用
JPWO2020018727A5 (https=)
Wang et al. Placental targeted drug delivery: a review of recent progress
JP2021505190A5 (https=)
RU2020100072A (ru) Иммуногенные композиции, содержащие cea, muc1 и tert
Aljabali et al. The dual promise of oncolytic viruses: selective targeting and therapeutic enhancement in cancer treatment